Niacin for Parkinson's disease

Seamon, Marissa; Purohit, Sharad; Giri, Banabihari; Baban, Babak; Morgan, John; Chong, Raymond; Wakade, Chandramohan

doi:10.1111/cen3.12553

Title: Niacin for Parkinson's disease

Journal Article · 27 December 2019 · Clinical and Experimental Neuroimmunology

DOI: https://doi.org/10.1111/cen3.12553 · OSTI ID:1580552

Seamon, Marissa ^[1]; Purohit, Sharad ^[2]; Giri, Banabihari ^[3]; Baban, Babak ^[4]; Morgan, John ^[5]; Chong, Raymond ^[6]; Wakade, Chandramohan ^[7]

Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Neuroscience Augusta University Augusta Georgia USA
Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Undergraduate Health Professionals Augusta University Augusta Georgia USA
Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Physical Therapy Augusta University Augusta Georgia USA
Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Oral Biology and Diagnostic Sciences Augusta University Augusta Georgia USA
Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Neurology Augusta University Augusta Georgia USA
Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Interdisciplinary Health Sciences Augusta University Augusta Georgia USA
Charlie Norwood VA Medical Center Augusta Georgia USA, Department of Neuroscience Augusta University Augusta Georgia USA, Department of Physical Therapy Augusta University Augusta Georgia USA, Department of Neurology Augusta University Augusta Georgia USA

Abstract Parkinson's disease (PD) is a neurodegenerative disease associated with progressive loss of motor function and cognitive decline occurring in 1% of the USA population. There is no cure for PD, and current treatment regimens are directed towards treating symptoms and not treating the underlying cause of the disease. Chronic neuroinflammation is associated with loss of neuronal cells, leading to motor and cognitive decline. Current clinical trials on drugs and nutraceuticals, such as coenzyme Q10 and niacin, are being carried out to delay progression and reduce damage by inflammatory molecules, such as reactive oxygen species and cytokines, in PD patients. In this review, we present available clinical trials and the role of niacin in reducing neuroinflammation in PD.

View Accepted Manuscript (Publisher)

Cite

Export

Save

Sponsoring Organization:: USDOE

OSTI ID:: 1580552

Journal Information:: Clinical and Experimental Neuroimmunology, Journal Name: Clinical and Experimental Neuroimmunology Journal Issue: 1 Vol. 11; ISSN 1759-1961

Publisher:: Wiley-BlackwellCopyright Statement

Country of Publication:: Country unknown/Code not available

Language:: English

References (117)

A Population-Based Investigation of Parkinson's Disease With and Without Dementia: Relationship to Age and Gender Mayeux, Richard Archives of Neurology, Vol. 49, Issue 5 https://doi.org/10.1001/archneur.1992.00530290076015	journal	May 1992
The Effect of Coenzyme Q10 Therapy in Parkinson Disease Could Be Symptomatic Horstink, Martin W. I. M. Archives of Neurology, Vol. 60, Issue 8 https://doi.org/10.1001/archneur.60.8.1170-b	journal	August 2003
PUMA-G, an IFN-γ-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily Schaub, Annette; Fütterer, Agnes; Pfeffer, Klaus European Journal of Immunology, Vol. 31, Issue 12 https://doi.org/10.1002/1521-4141(200112)31:12<3714::AID-IMMU3714>3.0.CO;2-1	journal	December 2001
Oxidative stress in Parkinson's disease Jenner, Peter Annals of Neurology, Vol. 53, Issue S3 https://doi.org/10.1002/ana.10483	journal	January 2003
Adenosine A _2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005) LeWitt, Peter A.; Guttman, M.; Tetrud, James W. Annals of Neurology, Vol. 63, Issue 3 https://doi.org/10.1002/ana.21315	journal	March 2008
Mitochondrial function in Parkinson's disease Schapira, Anthony H. V.; Mann, Vincent M.; Cooper, J. Mark Annals of Neurology, Vol. 32, Issue S1 https://doi.org/10.1002/ana.410320720	journal	January 1992
Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects Shults, Clifford W.; Haas, Richard H.; Passov, David Annals of Neurology, Vol. 42, Issue 2 https://doi.org/10.1002/ana.410420221	journal	August 1997
Low-dose niacin supplementation modulates GPR109A, niacin index and ameliorates Parkinson's disease symptoms without side effects Wakade, Chandramohan; Chong, Raymond; Bradley, Eric Clinical Case Reports, Vol. 3, Issue 7 https://doi.org/10.1002/ccr3.232	journal	June 2015
Microglia and neurodegeneration: The role of systemic inflammation Cunningham, Colm Glia, Vol. 61, Issue 1 https://doi.org/10.1002/glia.22350	journal	June 2012
Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress Coles, Lisa D.; Tuite, Paul J.; Öz, Gülin The Journal of Clinical Pharmacology, Vol. 58, Issue 2 https://doi.org/10.1002/jcph.1008	journal	September 2017
Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet®), sustained-release carbidopa-levodopa (Sinemet® CR), and carbidopa-levodopa-entacapone (: The Journal of Clinical Pharmacology Hsu, Ann; Yao, Hsuan-Ming; Gupta, Suneel The Journal of Clinical Pharmacology, Vol. 55, Issue 9 https://doi.org/10.1002/jcph.514	journal	May 2015
Flumazenil, a GABA antagonist, may improve features of Parkinson's disease Ondo, William G.; Hunter, Christine Movement Disorders, Vol. 18, Issue 6 https://doi.org/10.1002/mds.10426	journal	February 2003
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients Stern, Matthew B.; Marek, Kenneth L.; Friedman, Joseph Movement Disorders, Vol. 19, Issue 8 https://doi.org/10.1002/mds.20145	journal	January 2004
Intravenous flumazenil for Parkinson's disease: A single dose, double blind, placebo controlled, cross-over trial Ondo, William G.; Silay, Yavuz S. Movement Disorders, Vol. 21, Issue 10 https://doi.org/10.1002/mds.21022	journal	January 2006
Levodopa-induced dyskinesias Fabbrini, Giovanni; Brotchie, Jonathan M.; Grandas, Francisco Movement Disorders, Vol. 22, Issue 10 https://doi.org/10.1002/mds.21475	journal	January 2007
Zonisamide in patients with essential tremor and Parkinson's disease Bermejo, Pedro Emilio Movement Disorders, Vol. 22, Issue 14 https://doi.org/10.1002/mds.21717	journal	October 2007
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease: Glutathione in Parkinson's Disease Hauser, Robert A.; Lyons, Kelly E.; McClain, Terry Movement Disorders, Vol. 24, Issue 7 https://doi.org/10.1002/mds.22401	journal	February 2009
Long-term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease: Preladenant Long-Term Safety and Efficacy Factor, Stewart A.; Wolski, Kenneth; Togasaki, Daniel M. Movement Disorders, Vol. 28, Issue 6 https://doi.org/10.1002/mds.25395	journal	April 2013
A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease: PHASE I/IIA (IN)GSH IN PD Mischley, Laurie K.; Leverenz, James B.; Lau, Richard C. Movement Disorders, Vol. 30, Issue 12 https://doi.org/10.1002/mds.26351	journal	July 2015
MDS clinical diagnostic criteria for Parkinson's disease: MDS-PD Clinical Diagnostic Criteria Postuma, Ronald B.; Berg, Daniela; Stern, Matthew Movement Disorders, Vol. 30, Issue 12 https://doi.org/10.1002/mds.26424	journal	October 2015
Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD): Serum Immune Markers and PD Progression Williams-Gray, Caroline H.; Wijeyekoon, Ruwani; Yarnall, Alison J. Movement Disorders, Vol. 31, Issue 7 https://doi.org/10.1002/mds.26563	journal	March 2016
A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease: Randomized Trial of P2B001 in Early PD Olanow, C. Warren; Kieburtz, Karl; Leinonen, Mika Movement Disorders, Vol. 32, Issue 5 https://doi.org/10.1002/mds.26941	journal	April 2017
Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease: LETTERS: NEW OBSERVATIONS Yoritaka, Asako; Ohtsuka, Chigumi; Maeda, Tetsuya Movement Disorders, Vol. 33, Issue 9 https://doi.org/10.1002/mds.27472	journal	September 2018
Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease Pagan, Fernando L.; Hebron, Michaeline L.; Wilmarth, Barbara Pharmacology Research & Perspectives, Vol. 7, Issue 2 https://doi.org/10.1002/prp2.470	journal	March 2019
An open-label evaluation of the tolerability and safety of Stalevo� (carbidopa, levodopa and entacapone) in Parkinson?s disease patients experiencing wearing-off Koller, W.; Guarnieri, M.; Hubble, J. Journal of Neural Transmission, Vol. 112, Issue 2 https://doi.org/10.1007/s00702-004-0184-1	journal	October 2004
Effects of rotenone and pyridaben on complex I electron transfer and on mitochondrial nitric oxide synthase functional activity Navarro, Ana; Bández, Manuel J.; Gómez, Carmen Journal of Bioenergetics and Biomembranes, Vol. 42, Issue 5 https://doi.org/10.1007/s10863-010-9309-4	journal	October 2010
GPR109A and Vascular Inflammation Chai, Joshua T.; Digby, Janet E.; Choudhury, Robin P. Current Atherosclerosis Reports, Vol. 15, Issue 5 https://doi.org/10.1007/s11883-013-0325-9	journal	March 2013
Search for neurotoxins structurally related to 1-methyl-4-phenylpyridine (MPP+) in the pathogenesis of Parkinson's disease Ikeda, Hiroya; Markey, Carol J.; Markey, Sanford P. Brain Research, Vol. 575, Issue 2 https://doi.org/10.1016/0006-8993(92)90092-N	journal	March 1992
Impairment of glutamate uptake and absence of alterations in the energy-transducing ability of old rat brain mitochondria Vitorica, Javier; Clark, Arthur; Machado, Alberto Mechanisms of Ageing and Development, Vol. 29, Issue 3 https://doi.org/10.1016/0047-6374(85)90066-1	journal	March 1985
Nitric oxide synthase and neuronal vulnerability in parkinson's disease Hunot, S.; Boissière, F.; Faucheux, B. Neuroscience, Vol. 72, Issue 2 https://doi.org/10.1016/0306-4522(95)00578-1	journal	May 1996
The Generation of Hydrogen Peroxide, Superoxide Radical, and Hydroxyl Radical by 6-Hydroxydopamine, Dialuric Acid, and Related Cytotoxic Agents Cohen, Gerald; Heikkila, Richard E.; MacNamee, Dana Journal of Biological Chemistry, Vol. 249, Issue 8, p. 2447-2452 https://doi.org/10.1016/S0021-9258(19)42751-8	journal	April 1974
Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts Ma, Shuang Yong; Röyttä, Matias; Rinne, Juha O. Journal of the Neurological Sciences, Vol. 151, Issue 1 https://doi.org/10.1016/S0022-510X(97)00100-7	journal	October 1997
Zolpidem in Parkinson's disease Daniele, Antonio; Albanese, Alberto; Gainotti, Guido The Lancet, Vol. 349, Issue 9060 https://doi.org/10.1016/S0140-6736(05)62416-6	journal	April 1997
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial Rascol, O.; Brooks, Dj; Melamed, E. The Lancet, Vol. 365, Issue 9463 https://doi.org/10.1016/S0140-6736(05)71083-7	journal	March 2005
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial Athauda, Dilan; Maclagan, Kate; Skene, Simon S. The Lancet, Vol. 390, Issue 10103 https://doi.org/10.1016/S0140-6736(17)31585-4	journal	October 2017
Zonisamide has beneficial effects on Parkinson's disease patients Murata, Miho; Horiuchi, Emiko; Kanazawa, Ichiro Neuroscience Research, Vol. 41, Issue 4 https://doi.org/10.1016/S0168-0102(01)00298-X	journal	December 2001
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment Chaudhuri, K. Ray; Schapira, Anthony HV The Lancet Neurology, Vol. 8, Issue 5 https://doi.org/10.1016/S1474-4422(09)70068-7	journal	May 2009
Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial Hauser, Robert A.; Cantillon, Marc; Pourcher, Emmanuelle The Lancet Neurology, Vol. 10, Issue 3 https://doi.org/10.1016/S1474-4422(11)70012-6	journal	March 2011
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes Rascol, Olivier; Fitzer-Attas, Cheryl J.; Hauser, Robert The Lancet Neurology, Vol. 10, Issue 5 https://doi.org/10.1016/S1474-4422(11)70073-4	journal	May 2011
The genetics of Parkinson disease Deng, Hao; Wang, Peng; Jankovic, Joseph Ageing Research Reviews, Vol. 42 https://doi.org/10.1016/j.arr.2017.12.007	journal	March 2018
Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin Digby, Janet E.; McNeill, Eileen; Dyar, Oliver J. Atherosclerosis, Vol. 209, Issue 1 https://doi.org/10.1016/j.atherosclerosis.2009.08.045	journal	March 2010
Oxidative damage to macromolecules in human Parkinson disease and the rotenone model Sanders, Laurie H.; Timothy Greenamyre, J. Free Radical Biology and Medicine, Vol. 62 https://doi.org/10.1016/j.freeradbiomed.2013.01.003	journal	September 2013
Activation of Gpr109a, Receptor for Niacin and the Commensal Metabolite Butyrate, Suppresses Colonic Inflammation and Carcinogenesis Singh, Nagendra; Gurav, Ashish; Sivaprakasam, Sathish Immunity, Vol. 40, Issue 1 https://doi.org/10.1016/j.immuni.2013.12.007	journal	January 2014
Niacin modulates macrophage polarization in Parkinson's disease Wakade, Chandramohan; Giri, Banabihari; Malik, Aneeq Journal of Neuroimmunology, Vol. 320 https://doi.org/10.1016/j.jneuroim.2018.05.002	journal	July 2018
A novel treatment target for Parkinson's disease Wakade, Chandramohan; Chong, Raymond Journal of the Neurological Sciences, Vol. 347, Issue 1-2 https://doi.org/10.1016/j.jns.2014.10.024	journal	December 2014
Effects of duloxetine on motor and mood symptoms in Parkinson's disease: An open-label clinical experience Nishijima, Haruo; Ueno, Tatsuya; Kon, Tomoya Journal of the Neurological Sciences, Vol. 375 https://doi.org/10.1016/j.jns.2017.01.066	journal	April 2017
Zolpidem improves akinesia, dystonia and dyskinesia in advanced Parkinson’s disease Chen, Yen-Yu; Sy, Hiu-Ngar; Wu, Shey-Lin Journal of Clinical Neuroscience, Vol. 15, Issue 8 https://doi.org/10.1016/j.jocn.2007.07.082	journal	August 2008
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease Gerhard, Alexander; Pavese, Nicola; Hotton, Gary Neurobiology of Disease, Vol. 21, Issue 2 https://doi.org/10.1016/j.nbd.2005.08.002	journal	February 2006
Niaspan treatment induces neuroprotection after stroke Shehadah, Amjad; Chen, Jieli; Zacharek, Alex Neurobiology of Disease, Vol. 40, Issue 1 https://doi.org/10.1016/j.nbd.2010.05.034	journal	October 2010
Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease Taylor, Juliet M.; Main, Bevan S.; Crack, Peter J. Neurochemistry International, Vol. 62, Issue 5 https://doi.org/10.1016/j.neuint.2012.12.016	journal	April 2013
Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system Hernández-Romero, Mª Carmen; Delgado-Cortés, Mª José; Sarmiento, Manuel NeuroToxicology, Vol. 33, Issue 3 https://doi.org/10.1016/j.neuro.2012.01.018	journal	June 2012
Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease Kim, Sangjune; Kwon, Seung-Hwan; Kam, Tae-In Neuron, Vol. 103, Issue 4 https://doi.org/10.1016/j.neuron.2019.05.035	journal	August 2019
Niaspan reduces high-mobility group box 1/receptor for advanced glycation endproducts after stroke in type-1 diabetic rats Ye, X.; Chopp, M.; Liu, X. Neuroscience, Vol. 190 https://doi.org/10.1016/j.neuroscience.2011.06.004	journal	September 2011
Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial Fernandez, H. H.; Greeley, D. R.; Zweig, R. M. Parkinsonism & Related Disorders, Vol. 16, Issue 1 https://doi.org/10.1016/j.parkreldis.2009.06.008	journal	January 2010
Increased butyrate priming in the gut stalls microbiome associated-gastrointestinal inflammation and hepatic metabolic reprogramming in a mouse model of Gulf War Illness Seth, Ratanesh Kumar; Kimono, Diana; Alhasson, Firas Toxicology and Applied Pharmacology, Vol. 350 https://doi.org/10.1016/j.taap.2018.05.006	journal	July 2018
The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target Offermanns, S. Trends in Pharmacological Sciences, Vol. 27, Issue 7 https://doi.org/10.1016/j.tips.2006.05.008	journal	July 2006
Chronic systemic pesticide exposure reproduces features of Parkinson's disease Betarbet, Ranjita; Sherer, Todd B.; MacKenzie, Gillian Nature Neuroscience, Vol. 3, Issue 12 https://doi.org/10.1038/81834	journal	December 2000
The β-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages Rahman, Mahbubur; Muhammad, Sajjad; Khan, Mahtab A. Nature Communications, Vol. 5, Issue 1 https://doi.org/10.1038/ncomms4944	journal	May 2014
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates Collier, Timothy J.; Kanaan, Nicholas M.; Kordower, Jeffrey H. Nature Reviews Neuroscience, Vol. 12, Issue 6 https://doi.org/10.1038/nrn3039	journal	May 2011
Prevalence of Parkinson’s disease across North America Marras, C.; Beck, J. C.; Bower, J. H. npj Parkinson's Disease, Vol. 4, Issue 1 https://doi.org/10.1038/s41531-018-0058-0	journal	July 2018
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease Martin-Bastida, Antonio; Ward, Roberta J.; Newbould, Rexford Scientific Reports, Vol. 7, Issue 1 https://doi.org/10.1038/s41598-017-01402-2	journal	May 2017
Effect of Niacin on Inflammation and Angiogenesis in a Murine Model of Ulcerative Colitis Salem, Hesham Aly; Wadie, Walaa Scientific Reports, Vol. 7, Issue 1 https://doi.org/10.1038/s41598-017-07280-y	journal	August 2017
Lewy body diseases and multiple system atrophy as α-synucleinopathies Goedert, M.; Spillantini, M. G. Molecular Psychiatry, Vol. 3, Issue 6 https://doi.org/10.1038/sj.mp.4000458	journal	November 1998
Niacin Depletion in Parkinsonian Patients Treated with L-dopa, Benserazide and Carbidopa Bender, D. A.; Earl, C. J.; Lees, A. J. Clinical Science, Vol. 56, Issue 1 https://doi.org/10.1042/cs0560089	journal	January 1979
Interaction Among Mitochondria, Mitogen-Activated Protein Kinases, and Nuclear Factor-κB in Cellular Models of Parkinson's Disease Cassarino, David S.; Halvorsen, Erik M.; Swerdlow, Russell H. Journal of Neurochemistry, Vol. 74, Issue 4 https://doi.org/10.1046/j.1471-4159.2000.0741384.x	journal	April 2000
Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease Verschuur, Constant V. M.; Suwijn, Sven R.; Boel, Judith A. New England Journal of Medicine, Vol. 380, Issue 4 https://doi.org/10.1056/NEJMoa1809983	journal	January 2019
In vivo demonstration that -synuclein oligomers are toxic Winner, B.; Jappelli, R.; Maji, S. K. Proceedings of the National Academy of Sciences, Vol. 108, Issue 10 https://doi.org/10.1073/pnas.1100976108	journal	February 2011
-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies Spillantini, M. G.; Crowther, R. A.; Jakes, R. Proceedings of the National Academy of Sciences, Vol. 95, Issue 11 https://doi.org/10.1073/pnas.95.11.6469	journal	May 1998
Soluble, Prefibrillar α-Synuclein Oligomers Promote Complex I-dependent, Ca ²⁺ -induced Mitochondrial Dysfunction Luth, Eric S.; Stavrovskaya, Irina G.; Bartels, Tim Journal of Biological Chemistry, Vol. 289, Issue 31 https://doi.org/10.1074/jbc.M113.545749	journal	June 2014
Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid Wise, Alan; Foord, Steven M.; Fraser, Neil J. Journal of Biological Chemistry, Vol. 278, Issue 11 https://doi.org/10.1074/jbc.M210695200	journal	January 2003
Utilization of tryptophan, nicotinamide and nicotinic acid as precursors for nicotinamide nucleotide synthesis in isolated rat liver cells Bender, David A.; Olufunwa, Ronald British Journal of Nutrition, Vol. 59, Issue 2 https://doi.org/10.1079/BJN19880035	journal	March 1988
Niacin improved rigidity and bradykinesia in a Parkinson's disease patient but also caused unacceptable nightmares and skin rash—A case report Alisky, Joseph Martin Nutritional Neuroscience, Vol. 8, Issue 5-6 https://doi.org/10.1080/10284150500484638	journal	October 2005
Nicotinamide Treatment Provides Acute Neuroprotection and GFAP Regulation following Fluid Percussion Injury Holland, Michael A.; Tan, Arlene A.; Smith, Douglas C. Journal of Neurotrauma, Vol. 25, Issue 2 https://doi.org/10.1089/neu.2007.0312	journal	February 2008
Microglial/Macrophage Polarization Dynamics following Traumatic Brain Injury Kumar, Alok; Alvarez-Croda, Dulce-Mariely; Stoica, Bogdan A. Journal of Neurotrauma, Vol. 33, Issue 19 https://doi.org/10.1089/neu.2015.4268	journal	October 2016
Ageing and Parkinson'S Disease: Substantia Nigra Regional Selectivity Fearnley, Julian M.; Lees, Andrew J. Brain, Vol. 114, Issue 5 https://doi.org/10.1093/brain/114.5.2283	journal	January 1991
Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson’s disease Jucaite, Aurelija; Svenningsson, Per; Rinne, Juha O. Brain, Vol. 138, Issue 9 https://doi.org/10.1093/brain/awv184	journal	July 2015
Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of -synuclein in Parkinson's disease models Hebron, M. L.; Lonskaya, I.; Moussa, C. E. - H. Human Molecular Genetics, Vol. 22, Issue 16 https://doi.org/10.1093/hmg/ddt192	journal	May 2013
Oral Exposure to Paraquat Triggers Earlier Expression of Phosphorylated α-Synuclein in the Enteric Nervous System of A53T Mutant Human α-Synuclein Transgenic Mice Naudet, Nicolas; Antier, Emilie; Gaillard, Damien Journal of Neuropathology & Experimental Neurology, Vol. 76, Issue 12 https://doi.org/10.1093/jnen/nlx092	journal	October 2017
N-acetylcysteine Boosts Brain and Blood Glutathione in Gaucher and Parkinson Diseases Holmay, Mary J.; Terpstra, Melissa; Coles, Lisa D. Clinical Neuropharmacology, Vol. 36, Issue 4 https://doi.org/10.1097/WNF.0b013e31829ae713	journal	January 2013
Oral butyrate for mildly to moderately active Crohn's disease Sabatino, A. Di; Morera, R.; Ciccocioppo, R. Alimentary Pharmacology and Therapeutics, Vol. 22, Issue 9 https://doi.org/10.1111/j.1365-2036.2005.02639.x	journal	November 2005
Mitochondrial Complex I Deficiency in Parkinson's Disease Schapira, A. H. V.; Cooper, J. M.; Dexter, D. Journal of Neurochemistry, Vol. 54, Issue 3 https://doi.org/10.1111/j.1471-4159.1990.tb02325.x	journal	March 1990
Seeding induced by α-synuclein oligomers provides evidence for spreading of α-synuclein pathology Danzer, Karin M.; Krebs, Simon K.; Wolff, Michael Journal of Neurochemistry, Vol. 111, Issue 1 https://doi.org/10.1111/j.1471-4159.2009.06324.x	journal	October 2009
Characterization of Determinants of Ligand Binding to the Nicotinic Acid Receptor GPR109A (HM74A/PUMA-G) Tunaru, Sorin; Lättig, Jens; Kero, Jukka Molecular Pharmacology, Vol. 68, Issue 5 https://doi.org/10.1124/mol.105.015750	journal	August 2005
Evidence of Inflammatory System Involvement in Parkinson’s Disease Chao, Yinxia; Wong, Siew Cheng; Tan, Eng King BioMed Research International, Vol. 2014 https://doi.org/10.1155/2014/308654	journal	January 2014
GPR109A Is a G-protein-Coupled Receptor for the Bacterial Fermentation Product Butyrate and Functions as a Tumor Suppressor in Colon Thangaraju, M.; Cresci, G. A.; Liu, K. Cancer Research, Vol. 69, Issue 7 https://doi.org/10.1158/0008-5472.CAN-08-4466	journal	March 2009
The Niacin/Butyrate Receptor GPR109A Suppresses Mammary Tumorigenesis by Inhibiting Cell Survival Elangovan, S.; Pathania, R.; Ramachandran, S. Cancer Research, Vol. 74, Issue 4 https://doi.org/10.1158/0008-5472.CAN-13-1451	journal	December 2013
Treatment of End-of-Dose Wearing-Off in Parkinson’s Disease: Stalevo^® (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess^®/Comtan^® (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment Brooks, D. J.; Agid, Y.; Eggert, K. European Neurology, Vol. 53, Issue 4 https://doi.org/10.1159/000086479	journal	January 2005
Anti-Inflammatory Effects of Nicotinic Acid in Human Monocytes Are Mediated by GPR109A Dependent Mechanisms Digby, Janet E.; Martinez, Fernando; Jefferson, Andrew Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 32, Issue 3 https://doi.org/10.1161/ATVBAHA.111.241836	journal	March 2012
Niacin Treatment of Stroke Increases Synaptic Plasticity and Axon Growth in Rats Cui, Xu; Chopp, Michael; Zacharek, Alex Stroke, Vol. 41, Issue 9 https://doi.org/10.1161/STROKEAHA.110.589333	journal	September 2010
Microglia/Macrophage Polarization Dynamics Reveal Novel Mechanism of Injury Expansion After Focal Cerebral Ischemia Hu, Xiaoming; Li, Peiying; Guo, Yanling Stroke, Vol. 43, Issue 11 https://doi.org/10.1161/STROKEAHA.112.659656	journal	November 2012
GPR109A as an Anti-Inflammatory Receptor in Retinal Pigment Epithelial Cells and Its Relevance to Diabetic Retinopathy Gambhir, Deeksha; Ananth, Sudha; Veeranan-Karmegam, Rajalakshmi Investigative Opthalmology & Visual Science, Vol. 53, Issue 4 https://doi.org/10.1167/iovs.11-8447	journal	April 2012
GPR109A (PUMA-G/HM74A) mediates nicotinic acid–induced flushing Benyó, Zoltán; Gille, Andreas; Kero, Jukka Journal of Clinical Investigation, Vol. 115, Issue 12 https://doi.org/10.1172/JCI23626	journal	December 2005
Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells Lukasova, Martina; Malaval, Camille; Gille, Andreas Journal of Clinical Investigation, Vol. 121, Issue 3 https://doi.org/10.1172/JCI41651	journal	March 2011
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial Chagas, Marcos Hortes N.; Zuardi, Antonio W.; Tumas, Vitor Journal of Psychopharmacology, Vol. 28, Issue 11 https://doi.org/10.1177/0269881114550355	journal	September 2014
Macrophage imbalance (M1 vs. M2) and upregulation of mast cells in wall of ruptured human cerebral aneurysms: preliminary results Hasan, David; Chalouhi, Nohra; Jabbour, Pascal Journal of Neuroinflammation, Vol. 9, Issue 1 https://doi.org/10.1186/1742-2094-9-222	journal	September 2012
A randomized double-blind multi-center trial of hydrogen water for Parkinson’s disease: protocol and baseline characteristics Yoritaka, Asako; Abe, Takashi; Ohtsuka, Chigumi BMC Neurology, Vol. 16, Issue 1 https://doi.org/10.1186/s12883-016-0589-0	journal	May 2016
Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial Silveira, C. R. A.; MacKinley, J.; Coleman, K. BMC Neurology, Vol. 19, Issue 1 https://doi.org/10.1186/s12883-019-1252-3	journal	February 2019
α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration Harms, Ashley S.; Delic, Vedad; Thome, Aaron D. Acta Neuropathologica Communications, Vol. 5, Issue 1 https://doi.org/10.1186/s40478-017-0494-9	journal	November 2017
Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages Feingold, Kenneth R.; Moser, Arthur; Shigenaga, Judy K. Journal of Lipid Research, Vol. 55, Issue 12 https://doi.org/10.1194/jlr.M050955	journal	October 2014
Randomized trial of the adenosine A _2A receptor antagonist istradefylline in advanced PD Hauser, Robert A.; Hubble, Jean P.; Truong, Daniel D. Neurology, Vol. 61, Issue 3 https://doi.org/10.1212/01.WNL.0000081227.84197.0B	journal	August 2003
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease Stocchi, Fabrizio; Rascol, Olivier; Hauser, Robert A. Neurology, Vol. 88, Issue 23 https://doi.org/10.1212/WNL.0000000000004003	journal	May 2017
Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis Gagne, J. J.; Power, M. C. Neurology, Vol. 74, Issue 12 https://doi.org/10.1212/WNL.0b013e3181d5a4a3	journal	March 2010
Levodopa: Is toxicity a myth? Agid, Y. Neurology, Vol. 50, Issue 4 https://doi.org/10.1212/WNL.50.4.858	journal	April 1998
Zonisamide: A new drug for Parkinson's disease Murata, M. Drugs of Today, Vol. 46, Issue 4 https://doi.org/10.1358/dot.2010.46.4.1490077	journal	January 2010
Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in Mice Pan-Montojo, Francisco; Anichtchik, Oleg; Dening, Yanina PLoS ONE, Vol. 5, Issue 1 https://doi.org/10.1371/journal.pone.0008762	journal	January 2010
Effects of Niacin Restriction on Sirtuin and PARP Responses to Photodamage in Human Skin Benavente, Claudia A.; Schnell, Stephanie A.; Jacobson, Elaine L. PLoS ONE, Vol. 7, Issue 7 https://doi.org/10.1371/journal.pone.0042276	journal	July 2012
Non-Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Inflammatory Cytokines in Serum Lindqvist, Daniel; Kaufman, Eli; Brundin, Lena PLoS ONE, Vol. 7, Issue 10 https://doi.org/10.1371/journal.pone.0047387	journal	October 2012
Upregulation of GPR109A in Parkinson’s Disease Wakade, Chandramohan; Chong, Raymond; Bradley, Eric PLoS ONE, Vol. 9, Issue 10 https://doi.org/10.1371/journal.pone.0109818	journal	October 2014
Identification of Two Distinct Macrophage Subsets with Divergent Effects Causing either Neurotoxicity or Regeneration in the Injured Mouse Spinal Cord Kigerl, K. A.; Gensel, J. C.; Ankeny, D. P. Journal of Neuroscience, Vol. 29, Issue 43 https://doi.org/10.1523/JNEUROSCI.3257-09.2009	journal	October 2009
Novel Therapeutic Effects of the Anti-Convulsant, Zonisamide, on Parkinsons Disease Murata, M. Current Pharmaceutical Design, Vol. 10, Issue 6 https://doi.org/10.2174/1381612043453180	journal	February 2004
Decreased Activity of 3-Hydroxybutyrate Dehydrogenase in Diabetic Liver Mitochondria Roldan, A. G.; Del Castillo, E. J.; Boveris, A. Experimental Biology and Medicine, Vol. 137, Issue 3 https://doi.org/10.3181/00379727-137-35668	journal	July 1971
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease Aviles-Olmos, Iciar; Dickson, John; Kefalopoulou, Zinovia Journal of Parkinson's Disease, Vol. 4, Issue 3 https://doi.org/10.3233/JPD-140364	journal	July 2014
Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies Pagan, Fernando; Hebron, Michaeline; Valadez, Ellen H. Journal of Parkinson's Disease, Vol. 6, Issue 3 https://doi.org/10.3233/JPD-160867	journal	August 2016
Phase IIb Study of Intranasal Glutathione in Parkinson’s Disease Mischley, Laurie K.; Lau, Richard C.; Shankland, Eric G. Journal of Parkinson's Disease, Vol. 7, Issue 2 https://doi.org/10.3233/JPD-161040	journal	May 2017
α-Synuclein Activates Microglia by Inducing the Expressions of Matrix Metalloproteinases and the Subsequent Activation of Protease-Activated Receptor-1 Lee, Eun-Jung; Woo, Moon-Sook; Moon, Pyong-Gon The Journal of Immunology, Vol. 185, Issue 1 https://doi.org/10.4049/jimmunol.0903480	journal	May 2010
Variation in Chronic Nicotinamide Treatment after Traumatic Brain Injury Can Alter Components of Functional Recovery Independent of Histological Damage Hoane, Michael R.; Pierce, Jeremy L.; Kaufman, Nicholas A. Oxidative Medicine and Cellular Longevity, Vol. 1, Issue 1 https://doi.org/10.4161/oxim.1.1.6694	journal	January 2008
Treatment of Parkinson's Syndrome with L Dihydroxyphenylalanine (Levodopa) Mcdowell, Fletcher Annals of Internal Medicine, Vol. 72, Issue 1 https://doi.org/10.7326/0003-4819-72-1-29	journal	January 1970

Similar Records

Neuroprotection by immunomodulatory agents in animal models of Parkinson’s disease

Journal Article · 2018 · Neural Regeneration Research · OSTI ID:1628698

Martinez, Bridget; Peplow, Philip V.

Insights into Parkinson's disease models and neurotoxicity using non-invasive imaging

Journal Article · 2005 · Toxicology and Applied Pharmacology · OSTI ID:20721917

Sanchez-Pernaute, Rosario; Brownell, Anna-Liisa; Jenkins, Bruce G; +1 more

Regional Sensitivity to Neuroinflammation: In Vivo and In Vitro Studies

Journal Article · 2010 · Synapse · OSTI ID:1014363

Liraz-Zaltsman, S; Biegon, A; Liraz-Zaltsman, S; +6 more

Title: Niacin for Parkinson's disease

Citation Formats

References (117)

Similar Records

Related Subjects